Table 2.

Application of some NPs in glioblastoma combination

Combination therapy
Treatment modality	Nanocarriers	Cancer cell types	Loading efficiency	Release rate	Animal models	Refs.
Hyperthermia-chemotherapy	Fe(Salen)	U251	-	-	U251 bearing Mice	[155]
Magnetite chemo-hyperthermia	Magnetite nanoparticles functionalized with folic acid ligand	C6	65.6%	10 min pH 7.4 43 °C 44.4%	-	[156]
chemo-photothermal therapy	PLGA functionalized with angiopep-2 peptide	U87MG	78.6%	-	Tumor bearing mice	[157]
Chemo-immunotherapyc	MSN-SS-CD-iRGD&1MT nanoparticle	GL261-luc	-	-	GL261-luc bearing C57BL/6 mice	[158]
Magnetothermal chemotherapy	Fe-TSL	U87 cells and U251 cells	19.75%	80% in 10 min at 42 °C	-	[159]
Hyperthermia and chemotherapy	lipid-based magnetic nanovectors	U-87 MG	4.1%	pH 7.4 7 day 65.8%	-	[160]
Gene therapy hyperthermia	Cationic liposomes	U251-S	-	-	Tumor bearing mice	[161]
Chemotherapy and hyperthermia	Liposomes	C6	-	80% after 10 min, 37 °C	C6 bearing rats	[162]
Photodynamic Therapy and Chemotherapy	Cu2-xSe nanoparticles	U87	-	72 h, 11% at pH = 7.4	mice bearing orthotopic malignant glioblastoma	[163]
Ultrasound, Chemotherapy	lipid-polymer	T98G U251 U87 MG	2.5%	pH 4.5, 48 h, 12.5%	-	[164]
Radiation- gene therapy-immunotherapy	solid lipid nanoparticle (SLN) functionalized with cyclic peptide iRGD	U87 GL261	-	-	Glioblastoma bearing mouse	[165]
Radiotherapy and Immunotherapy	AuNPs	G261	-	-	tumor-bearing C57BL/6 mice G261 tumor-bearing mice	[166]